Pacer Advisors, Inc. Nurix Therapeutics, Inc. Transaction History

Pacer Advisors, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$12.02 - $21.3 $2,452 - $4,345	-204 Reduced 20.71%	781 $16,000
Q1 2024 May 10, 2024	BUY	$7.77 - $15.66 $7,653 - $15,425	985 New	985 $14,000
Q2 2021 Jul 21, 2021	SELL	$24.21 - $35.89 $38,276 - $56,742	-1,581 Closed	0 $0
Q1 2021 Apr 05, 2021	BUY	$26.98 - $50.17 $28,113 - $52,277	1,042 Added 193.32%	1,581 $49,000
Q4 2020 Jan 20, 2021	BUY	$22.85 - $48.44 $12,316 - $26,109	539 New	539 $18,000

181

68.1M

78K

53.8K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $935M
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Pacer Advisors, Inc. with notifications on news.